Sugi Predict

Sugi Predict / Compounds / SCHEMBL8344035

SCHEMBL8344035

SCHEMBL8344035

CC(C)(C)OC(=O)N1CCC[C@@]1(C)C=O

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GRIN2B Q13224 1/20 0.41
▸ GRIN2C Q14957 1/20 0.41
▸ USP2 O75604 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CTSK P43235 1/20 0.36
▸ JAK3 P52333 2/20 0.35
▸ HPGD P15428 1/20 0.35
▸ EPHX1 P07099 1/20 0.33
▸ NR1H2 P55055 1/20 0.32
▸ PREP P48147 1/20 0.32
▸ EPHX2 P34913 1/20 0.32
▸ CHRM2 P08172 1/20 0.32
▸ CHRM1 P11229 1/20 0.32
▸ CHRM3 P20309 1/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11963181 1.00 GRIN2B (0.41) GRIN2BGRIN2CUSP2SMN1; SMN2CTSK
SCHEMBL705138 1.00 GRIN2B (0.41) GRIN2BGRIN2CUSP2SMN1; SMN2CTSK
SCHEMBL27092767 0.95 GRIN2B (0.38) GRIN2BGRIN2CUSP2SMN1; SMN2CTSK
SCHEMBL22231289 0.90 USP2 (0.39) GRIN2BGRIN2CUSP2SMN1; SMN2CTSK
SCHEMBL27092766 0.86 GRIN2B (0.40) GRIN2BGRIN2CUSP2SMN1; SMN2CTSK
SCHEMBL31105130 0.84 GRIN2B (0.39) GRIN2BGRIN2CUSP2SMN1; SMN2CTSK
SCHEMBL29530324 0.82 GRIN2B (0.33) GRIN2BGRIN2CCTSK
SCHEMBL27092793 0.81 GRIN2B (0.37) GRIN2BGRIN2CUSP2SMN1; SMN2CTSK
SCHEMBL31566932 0.80 GRIN2B (0.37) GRIN2BGRIN2CUSP2SMN1; SMN2CTSK
SCHEMBL475482 0.80 GRIN2B (0.44) GRIN2BGRIN2CUSP2SMN1; SMN2CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049054-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA AS (DK) 2026-02-19 — — US disclosed
EP-4676591-A2 SMALL MOLECULE FSH RECEPTOR MODULATORS Ferring B.V. (NL) 2026-01-14 — — EP disclosed
US-20250340548-A1 KRAS G12C INHIBITORS FRONTIER MEDICINES CORP (US) 2025-11-06 — — US disclosed
US-12391644-B2 Potassium channel inhibitors SANIONA A/S (DK) 2025-08-19 — — US disclosed
EP-3941903-B1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA AS (DK) 2025-07-16 — — EP disclosed
US-12291539-B2 KRAS G12C inhibitors FRONTIER MEDICINES CORPORATION (US) 2025-05-06 — — US disclosed
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-04-24 — — US disclosed
WO-2025064718-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-03-27 — — WO disclosed
WO-2025051148-A1 NITROGEN-CONTAINING HETEROARYL COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 北京鞍石生物科技股份有限公司 2025-03-13 — — WO disclosed
US-20250019387-A1 KRAS G12C INHIBITORS FRONTIER MEDICINES CORPORATION 2025-01-16 — — US disclosed
US-20220169605-A1 NOVEL SUBSTITUTED SULFONYLUREA DERIVATIVES ZYDUS LIFESCIENCES LIMITED (IN) 2022-06-02 — — US disclosed
US-20220169602-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2022-06-02 — — US disclosed
WO-2022066734-A1 PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER SCORPION THERAPEUTICS, INC. (US) 2022-03-31 — — WO disclosed
EP-3941903-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Saniona A/S (DK) 2022-01-26 — — EP disclosed
CN-113631538-A Novel potassium channel inhibitors 萨尼奥纳有限责任公司 2021-11-09 — — CN disclosed
CN-113474333-A Novel substituted sulfonylurea derivatives 卡迪拉保健有限公司 2021-10-01 — — CN disclosed
US-5872135-A ENZYME INHIBITORS MERK & CO., INC. (US) 1999-02-16 — — US disclosed
US-5869682-A Inhibitors of farnesyl-protein transferase MERCK & CO., INC. (US) 1999-02-09 — — US disclosed
US-5661161-A Inhibitors of farnesyl-protein transferase MERCK & CO., INC. (US) 1997-08-26 — — US disclosed
WO-1996010035-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1996-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169605-A1 NOVEL SUBSTITUTED SULFONYLUREA DERIVATIVES NOD1, NLRP3, IL1R1 GRIN2B 3149/4885GRIN2C 3578/4885USP2 3406/4885
US-12391644-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 GRIN2B 251/4885GRIN2C 214/4885USP2 3540/4885
US-20220169602-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 GRIN2B 222/4885GRIN2C 208/4885USP2 3015/4885
US-12291539-B2 KRAS G12C inhibitors KRAS, NRAS, HRAS GRIN2B 4510/4885GRIN2C 3675/4885USP2 953/4885
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS MYC, KRAS, NRAS GRIN2B 4557/4885GRIN2C 4405/4885USP2 1781/4885
US-20250340548-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS GRIN2B 4510/4885GRIN2C 3675/4885USP2 953/4885
US-20260049054-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SCN10A, KCNK10, KCNJ2 GRIN2B 992/4885GRIN2C 1001/4885USP2 4447/4885
US-20250019387-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS GRIN2B 4510/4885GRIN2C 3675/4885USP2 953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.